Version 1
: Received: 20 October 2023 / Approved: 23 October 2023 / Online: 25 October 2023 (09:15:59 CEST)
Version 2
: Received: 17 April 2024 / Approved: 18 April 2024 / Online: 18 April 2024 (07:51:28 CEST)
How to cite:
Łasut-Szyszka, B.; Gdowicz-Kłosok, A.; Krześniak, M.; Głowala-Kosińska, M.; Będzińska, A.; Rusin, M. Strong Activation of p53 by Actinomycin D and Nutlin-3a Overcomes Resistance of Cancer Cells to the Pro-apoptotic Activity of FAS Ligand. Preprints2023, 2023101608. https://doi.org/10.20944/preprints202310.1608.v1
Łasut-Szyszka, B.; Gdowicz-Kłosok, A.; Krześniak, M.; Głowala-Kosińska, M.; Będzińska, A.; Rusin, M. Strong Activation of p53 by Actinomycin D and Nutlin-3a Overcomes Resistance of Cancer Cells to the Pro-apoptotic Activity of FAS Ligand. Preprints 2023, 2023101608. https://doi.org/10.20944/preprints202310.1608.v1
Łasut-Szyszka, B.; Gdowicz-Kłosok, A.; Krześniak, M.; Głowala-Kosińska, M.; Będzińska, A.; Rusin, M. Strong Activation of p53 by Actinomycin D and Nutlin-3a Overcomes Resistance of Cancer Cells to the Pro-apoptotic Activity of FAS Ligand. Preprints2023, 2023101608. https://doi.org/10.20944/preprints202310.1608.v1
APA Style
Łasut-Szyszka, B., Gdowicz-Kłosok, A., Krześniak, M., Głowala-Kosińska, M., Będzińska, A., & Rusin, M. (2023). Strong Activation of p53 by Actinomycin D and Nutlin-3a Overcomes Resistance of Cancer Cells to the Pro-apoptotic Activity of FAS Ligand. Preprints. https://doi.org/10.20944/preprints202310.1608.v1
Chicago/Turabian Style
Łasut-Szyszka, B., Agnieszka Będzińska and Marek Rusin. 2023 "Strong Activation of p53 by Actinomycin D and Nutlin-3a Overcomes Resistance of Cancer Cells to the Pro-apoptotic Activity of FAS Ligand" Preprints. https://doi.org/10.20944/preprints202310.1608.v1
Abstract
The p53 protein activates pro-apoptotic gene FAS, which encodes death receptor for the FAS ligand (FASLG). Cancer cells are resistant to apoptosis triggered by FASLG. We found that actinomycin D and nutlin-3a (ActD+Nut3a) synergized in activation of p53 and in the induction of pro-apoptotic genes; however, the apoptotic cells were infrequent. We hypothesized that this drug combination sensitizes cancer cells to the pro-apoptotic activity of FASLG. We exposed various cancer cell lines to ActD+Nut3a for 45h and next we treated cells with recombinant FASLG. We observed apoptosis by flow cytometry and by activation status of caspase-3, -8, -9, and -10. The cell viability was determined by the MTS assay and cell staining on culture plates. Actinomycin D and nutlin-3a strongly synergized in sensitizing cells to apoptosis triggered by FASLG. This combination killed more than 99% of cells within 5h. The cell death was accompanied by a strong activation of all examined caspases. In engineered p53-deficient cells this pro-apoptotic effect was completely lost. Therefore, the combination of ActD+Nut3a activates p53 in a way, which overcomes the resistance of cancer cells to apoptosis triggered by FASLG.
Keywords
p53; FASLG; apoptosis; death receptor; MDM2; cancer therapy
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
*
